Reducing the risk of P. vivax after falciparum infections in co-endemic areas - a randomized controlled trial (PRIMA)
 
Aim:

To simplify malaria treatment in co-endemic areas, by assessing the use of primaquine radical cure in Plasmodium falciparum patients to reduce the risk of subsequent P. vivax.

Rationale:

In the Asia Pacific, National Malaria Control Programs repeatedly call for better approaches for radical cure, to meet their malaria elimination targets1. 

In the Asia Pacific region, the Horn of Africa and Americas, malaria is mostly caused by two species Plasmodium falciparum and P. vivax. Unlike P. falciparum, P. vivax forms dormant liver stages that reactivate weeks or months following an acute infection causing active disease. The WHO currently recommends a treatment with primaquine to kill the liver stage parasites, referred to as radical cure. But this is only indicated in patients presenting with P. vivax malaria. However recent evidence2,3 suggests that the risk of relapsing P. vivax malaria is higher after an acute P. falciparum infection than the natural relapse rate or the rate of reinfection would suggest. This suggests that in some locations a universal policy of primaquine radical cure for both falciparum and vivax malaria maybe warranted

To explore this strategy, we are conducting a randomised controlled trial to assess the safety and efficacy of primaquine treatment in patients with P. falciparum to reduce the risk of subsequent P. vivax episodes.

Implications for policy and practice:

Recurrent episodes of P. vivax put a strain on healthcare systems. A unified treatment policy for malaria might confer significant individual, public health and operational benefits in regions co-endemic for P. falciparum and P. vivax. The optimal use of limited financial resources could necessitate strategies for treating P. vivax through universal radical cure.

Our research locations:
  • Bangladesh
  • Ethiopia
  • Indonesia

 

 

 

 

 

Study title:

Reducing the risk of P. vivax after falciparum infections in co-endemic areas - a randomized controlled trial (PRIMA).

Study purpose:
  • To compare the safety and efficacy of a high dose primaquine treatment in G6PD normal patients with P. falciparum to reduce the risk of subsequent P. vivax episodes to current standard practice.
Objectives:

Primary

  • To assess the safety and efficacy of a 7-day course of high dose primaquine treatment regimen in preventing recurrent symptomatic P. vivax parasitaemia in G6PD normal patients following uncomplicated P. falciparum malaria.

Secondary

  • To assess the efficacy of a 7-day course of high dose primaquine treatment regimen in preventing recurrent symptomatic and asymptomatic P. vivax and P. falciparum parasitaemia
  • To assess the relationship between Hb and G6PD activity over time

For more information visit the clinical trials website.  

Project dates:

The trial is complete. 

Project team:

Chief investigator:

Project manager:

Investigators:

  • Dr Benedikt Ley – Menzies School of Health Research
  • Professor Ric Price -Menzies School of Health Research
  • Professor Asrat Hailu – Addis Abeba University, Ethiopia
  • Dr Tamiru Degaga -ArbaMinch University, Ethiopia
  • Dr Shafiul Alam –icddr,b, Bangladesh
  • Dr Wasif Ali Khan – icddr,b, Bangladesh
  • Professor Inge Sutanto- Faculty of Medicine Universitas, Indonesia
  • Professor Kevin Baird- Eijkman-Oxford Clinical Research Unit (EOCRU), Indonesia

 

 

 

 

 

 

Collaborators:
Funders:
  • Australian Academy of Science
    • The funding is provided by the Australian Academy of Science, on behalf of the Department of Industry, Innovation and Science. The Regional Collaborations Programme is supported by the Australian Government under the National Innovation and Science Agenda.
       
  • Bill and Melinda Gates Foundation.
Photo credits:
  • Pearl Gan in association with OUCRU, Vietnam and EOCRU, Indonesia.
  1. Hidden malaria life cycle discovered in the spleen

    Hidden malaria life cycle discovered in the spleen

    Date

    Ground-breaking studies published today in the New England Journal of Medicine and PLOS Medicine have found large numbers of malaria parasites hiding in the human spleen where they actively multiply in a previously unrecognised life cycle.

  2. Regional research set to get digital boost

    Regional research set to get digital boost

    Date

    Resources Regional Collaborations Programme COVID-19 Digital Grants, recognises A/Prof Kamala Ley-Thriemer, Dr Jo Wapling and Dr Chris Lowbridge.

  3. Five medical research projects recognised in the Northern Territory

    Five medical research projects recognised in the Northern Territory

    Date

    Five researchers based at Menzies have received recognition in the form of Investigator Grants from the NHMRC and the MRFF.

  4. Media Release | Malaria researcher awarded national fellowship

    Media Release | Malaria researcher awarded national fellowship

    Date

    Menzies School of Health (Menzies) researcher Dr Kamala Thriemer has been awarded a prestigious $1.25 million CSL Centenary Fellowship to develop and optimise treatment programs against vivax malaria in SE Asia and the Horn of Africa.

  5. Media Release | $2.5 million CSL Centenary Fellowships announced

    Media Release | $2.5 million CSL Centenary Fellowships announced

    Date

    Two Australian scientists have each been awarded AUD$1.25 million CSL Centenary Fellowships over five years to improve treatments for two of the world’s biggest health challenges: malaria and cancer.

  6. New Research Pinpoints Faster Treatment to Cure Vivax Malaria

    New Research Pinpoints Faster Treatment to Cure Vivax Malaria

    Date

    A new research study has shown that a seven-day treatment with a high dose of an anti-malaria drug can be tolerated by patients

  7. New study shows faster way to cure vivax malaria

    New study shows faster way to cure vivax malaria

    Date

    A large clinical trial in Africa and Asia has shown that a 7 day course of high dose primaquine, a drug used to treat P. vivax malaria, is well tolerated.

Study protocol

  • Thriemer, K., Degaga, T. S., Christian, M., Alam, M. S., Ley, B., Hossain, M. S., Kibria, M. G., Tego, T. T., Abate, D. T., Weston, S., Karahalios, A., Rajasekhar, M., Simpson, J. A., Rumaseb, A., Mnjala, H., Lee, G., Anose, R. T., Kidane, F. G., Woyessa, A., Baird, K., … Price, R. N. (2022). Reducing the risk of Plasmodium vivax after falciparum infections in co-endemic areas-a randomized controlled trial (PRIMA). Trials, 23(1), 416. https://doi.org/10.1186/s13063-022-06364-z